Actavis Plc urged a U.S. appeals court on Monday to allow it to discontinue a top-selling Alzheimer’s drug in favor of a pricier extended-release version, a move that New York’s attorney general has said would suppress generic competition.
A three-judge panel of the 2nd U.S. Circuit Court of Appeals peppered attorneys for Actavis and for the attorney general with questions, although the judges gave no clear indication of how they would rule.
New York Attorney General Eric Schneiderman filed an antitrust lawsuit against Dublin-based Actavis last year in Manhattan federal court after the company said it was planning to discontinue Namenda IR in favor of Namenda XR. The two drugs have the same active ingredient, but Namenda XR is taken once daily instead of twice.
The lawsuit claimed that by forcing patients to switch to the new version, Actavis hoped to stave off competition from drug maker.
Full Content: Houston Chronicle
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Public Interest Groups Push for Rehearing on FCC Net Neutrality Case
Feb 18, 2025 by
CPI
Australian Regulator Backs Virgin Australia-Qatar Airways Alliance
Feb 18, 2025 by
CPI
EU Scales Back AI Regulations to Compete with US in Global Tech Race
Feb 18, 2025 by
CPI
Democratic Lawmakers Raise Concerns Over Musk’s Task Force and Taxpayer Data Security
Feb 18, 2025 by
CPI
UK’s CMA Provisionally Approves Poultry Feed Merger
Feb 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon